Home › Biocartis Issues Q3 Update, Raises €32.7M, Inks US Distribution Deal

Biocartis Issues Q3 Update, Raises €32.7M, Inks US Distribution Deal

Nov 17, 2016

NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis Group issued an update on its business during the third quarter of fiscal year 2016, and announced €32.7 million ($34.7 million) in private financing and a US distribution deal with Thermo Fisher Scientific for its Idylla diagnostics platform and assays.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS approaches for Microbiome Studies

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS approaches for Microbiome Studies

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

What's Popular?

In PCR

  1. Curetis to Cut 30 Percent of Workforce as Part of Strategic Restructuring

  2. Synlab Pharma, Biotype Collaborate on Gastrointestinal, Endometrial Cancers

  3. ChromaCode Tackling Tick-Borne Illness Testing With Multiplex Molecular Panel

    Premium

  4. HiberGene Gets CE Mark for Rapid Flu Combo MDx

  5. PredictImmune Wins £100K Grant for Study of IBD Prognostic

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.